In an international joint double-blind trial on 452 patients with complicated urinary tract infections Shionogi’s injectable siderophore cephalosporin cefiderocol (S-649266) outperformed other cephalosporin antibiotics. Shionogi plans to apply for approval of FDA in the first half of 2017.

Shionogi news release, January 13, 2017